Inclusion Criteria:  Male or female patients aged more than 18 years old; ECOG PS：0-2; Subjects with histologically or cytologically confirmed locally advanced and/or advanced esophageal squamous cell carcinoma(ESCC); For local advanced or advanced ESCC, disease progression occurred after 1 or more lines systemic treatment previously; Have received anlotinib combined with PD-1 inhibitor treatment.  Exclusion Criteria:  have used Anlotinib before; mixed with small cell cancer and/or other kinds of cancer ; Previously (within 5 years) or presently suffering from other malignancies; Symptomatic or uncontrolled brain metastases; Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months or serious cardiac arrhythmia requiring medication; Pregnancy or lactation. -